Chengfei Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Chengfei Liu has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Banruo Xianyu
Key Laboratory of Organic Optoelectronics & Molecular Engineering and Laboratory of Flexible Electronics Technology, Department of Chemistry, Tsinghua University, Beijing 100084
1 shared publicationBingbing Shi
Department of Chemistry, University of Utah, Salt Lake City, UT 84112
1 shared publication- Chaowei He
Department of Chemistry Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology Tsinghua University Beijing People's Republic of China
1 shared publication Hajar Sepehrpour
Department of Chemistry, University of Utah, Salt Lake City, UT 84112
1 shared publication- Huaping Xu
Tsinghua University
1 shared publication - Hui Li
Jiangxi Province Key Laboratory of Functional Crystalline Materials Chemistry, School of Chemistry and Chemical Engineering, Jiangxi University of Science and Technology, Ganzhou 341000, Jiangxi Province, P.R. China
1 shared publication
Latest Publications
- 1 February 2025
- Published by Chinese Chemical Society in CCS Chemistry
- Vol. 7 (2) , 403-415
Intracellular Construction of Topological Polymer Networks to Destruct Organelles
- 1 February 2025
- Published by Chinese Chemical Society in CCS Chemistry
- Vol. 7 (2) , 403-415
Intracellular Construction of Topological Polymer Networks to Destruct Organelles
- 23 November 2020
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 117 (49) , 30942-30948
β-Cyclodextrin modified Pt(II) metallacycle-based supramolecular hyperbranched polymer assemblies for DOX delivery to liver cancer cells
Significance: The development of chemotherapeutic drugs for cancer treatment has been limited by problems such as adverse side effects and inefficient performance of the drugs. To deliver multiple anticancer drugs for accurate and synergistic liver cancer treatment, a Pt(II) metallacycle-based drug delivery system, with endogenous redox and nitric oxide stimuli responsiveness and two chemotherapeutic agents is designed via the orthogonal self-assembly strategy. In vitro studies demonstrate that this system has good ability to deliver hydrophobic anticancer drug doxorubicin to HepG2 liver cancer cells. It also efficiently inhibits tumor cell growth for enhanced liver cancer treatment. This study provides an opportunity for the further design of metallacycle-based drug delivery systems for cancer therapy.
- 23 November 2020
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 117 (49) , 30942-30948
β-Cyclodextrin modified Pt(II) metallacycle-based supramolecular hyperbranched polymer assemblies for DOX delivery to liver cancer cells
Significance: The development of chemotherapeutic drugs for cancer treatment has been limited by problems such as adverse side effects and inefficient performance of the drugs. To deliver multiple anticancer drugs for accurate and synergistic liver cancer treatment, a Pt(II) metallacycle-based drug delivery system, with endogenous redox and nitric oxide stimuli responsiveness and two chemotherapeutic agents is designed via the orthogonal self-assembly strategy. In vitro studies demonstrate that this system has good ability to deliver hydrophobic anticancer drug doxorubicin to HepG2 liver cancer cells. It also efficiently inhibits tumor cell growth for enhanced liver cancer treatment. This study provides an opportunity for the further design of metallacycle-based drug delivery systems for cancer therapy.